The good news is there was a huge trial in Alport syndrome published

The bad news is it was on bardoxolone. Tweetorial catch-up here.

✳️ #TenTweetNephJC ✳️

This week CARDINAL - the largest ever RCT in patients with Alport Syndrome 🧵👇 pic.twitter.com/wrAxJoz1GJ

— Nephrology Journal Club (@NephJC) January 28, 2023

Freely Filtered does STOP ACE

Episode 055: The Filtrate try to figure out STOP ACE with the assistance of Laurie Tomlinson.

The CARDINAL Visual Abstract

Does Bardoxolone help patients with Alport’s Syndrome? Dr M Abdul Qader explains graphically.

View fullsize

IgA and steroids: the saga continues

Drug reps pitching you Nefecon? Catch-up with the RCT in our #TenTweetNephJC tweetorial

#TenTweetNephJC returns in 2023! Catch-up rapidly with the biggest trials in nephrology.

Up first is NefIgArd.

We all say we hate steroids, but really we love their efficacy but hate their side-effects, right?

IgA nephropathy is again the subject of a steroid trial🧵 pic.twitter.com/sh0xtKPhsP

— Nephrology Journal Club (@NephJC) January 20, 2023

NefIgArd trial : Visual Abstract

Check out the Delightful Visual Abstract for the NefIgArd trial by Priti Meena